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ABSTRACT 
The potential benefit of nanoparticles (NPs) as a colloidal delivery system for pharmaceutical relevance has earned substantial concern in the past 
decades. Fatality rate due to cancer sustained to hike; advances in nanotechnology have quite become a trenchant approach for enhancing effective 
drug targeting to cancer tissues by circumventing all the imperfections of traditional chemotherapy. Inhalation drug delivery directly targeting the 
lungs through respiratory tract is a rapidly maturing field of research and most recently explored approaches for both local and systemic therapy. 
With the recent advances in synthesis and manipulation of nanoparticles, inhalation drug delivery has shown great impact on pulmonary practice. 
Inhalation drug delivery has diverse actions over traditional chemotherapy including a) non-invasive b) avoiding first pass metabolism and 
systemic toxicity c) minimized frequent dosing and d) target delivery of drug to the lung epithelium thereby enhancing local drug concentrations. 
Dry powder inhalers, meter dose inhalers and nebulizers are some few efficient methods to deliver therapeutic agents directly targeting to the 
lungs. The ultimatum of inhalation therapy is to generate particles with an ample range of particle sizes. With the recent interest in the development 
of pulmonary targeted therapy, this review presents how the inhalation drug delivery overcomes conventional chemotherapy and focuses the 
recent treatment modalities that have been established for pulmonary carcinoma by the route of inhalation as well as discusses the advantages of 
inhalation drug delivery.  
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INTRODUCTION  
Lung cancer was a rare disease until the beginning of the 20th 
century. Now, it is expected to cause 10 million deaths per year 
worldwide by the year 2030 [1]. The global incidence is 14%, 
whereas it constitutes 6.8% of all cancers in India. The lungs are a 
frequent site of metastasis and >90% of deaths due to lung cancer 
are attributed to the metastatic process [2, 3]. A large number of 
lung cancers are associated with smoking cigarette; however other 
factors such as environmental influences and radon or nutrition may 
also be involved [4]. Tobacco content of smoke, the polycyclic 
aromatic hydrocarbons (PAHs) such as benzo (a) pyrene [B (a) P], 
play a crucial role in the induction of pulmonary carcinoma [5]. B 
(a)P has been consigned as human carcinogen by the International 
agency for research on cancer [6]. Conventional modalities such as, 
chemotherapy or radiotherapy or their combinations are considered 
to be the foremost preventive choices for lung cancer patients [7]. 
However, the systemic administration of comprehensive 
chemotherapeutic agents causes marked toxicities and nasty side 
effects because the chemopreventive agents used act on tumor cells 
as well as normal cells [8, 9].  
Furthermore, the delivery coherence of intravenously administered 
agents to the lungs is very little because they are diluted in the 
systemic circulation and thus, therapies are oft lousy and survival 
times are very short [7-9]. Direct local delivery of chemotherapeutic 
agents to the sites of lung cancer offers a desirable alternative 
approach because it allows the concentrated delivery of 
chemopreventive agents to tumor sites [8-11]. Inhalation 
chemotherapy is one such direct delivery of chemotherapeutic 
agents to lung cancer which offers wide range of assistance over 
other modes of administration like high local concentration, 
increased selectivity and lower systemic exposure, etc. The lung is a 
directly accessible organ from the exterior [12, 13]. Thus, inhalation 
therapy represents an attractive treatment model for the targeted 
delivery of chemopreventive agents to their desired site of action. 
Moreover, inhalation model represents a non-invasive substitute for 
systemic delivery of pharmaceuticals (e. g. proteins and peptides); 
the lower enzymatic activity (contrast to the oral delivery), thin 
epithelial air-blood barrier and large alveolar surface area allow 
rapid absorption of macromolecules from the alveolar airspace [14]. 
In general, the supremacy of inhalation therapy depends on the 
mechanism and rate of elimination in the respiratory tract. Once the 
curative agent has been deposited in the lung, destruction is 
immediately initiated, reducing the initial high local concentrations 
in lung tissue [15–17]. Additionally, direct delivery of the 
compounds dodge first-pass metabolism by the liver, permits the 
majority of the compound to reach the target organ (i.e., lungs with 
metastatic deposits) while the systemic exposure is limit.  
The origin of inhalation therapies flashes in back 40th century ago to 
India, where people used to smoke the leaves of the Atropa 
belladonna plant for the prevention of cough. The evolution of an 
inhalation therapy which is effective and secure depends not only on 
a pharmacologically active molecule but also on a delivery system 
and its applications [18]. Inhaled drug delivery is widely used to 
treat asthma, chronic obstructive pulmonary disease (COPD) and 
cystic fibrosis has shown promising alternate delivery method for 
lung cancer chemotherapeutics. Inhalation chemotherapy was first 
described by Shevchenko and Resnik in 1968 [19].  
The inhalation delivery of drug was tested in dogs and eventually in 
58 patients. Anticancer effect was perceived in 24 patients but the 
data were arduous to interpret because of the simultaneous use of 
radiotherapy. But still, this initial trial established the feasibility of 
administering chemotherapy by inhalation mode of delivery. Since 
then, a wide range of chemotherapeutic agents including 
Temozolomide [9], Cisplatin [20], Polyphenon E [21], Cyclosporine 
[22] and 5-Fluorouracil [23] administered by inhalation have been 
evaluated in preclinical models. Administration of 5-fluorouracil by 
inhalation mode in dogs were tested by Tatsumura et al. [24] and 
established elevated levels of the drug deposition in the trachea, 
hilar bronchi and regional nodes. After that, the same research 
group treated 10 patients with chronic lung tumors with 5-
fluorouracil administered via supersonic nebulizer at a dose of 250 
mg twice daily for 2 to 3 days per week. They observed antitumor 
efficacy with two complete and four partial responses. In addition to 
inhaled chemotherapeutic agent’s administration of cytokines, 
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interferons, siRNA and nano-formulations were tried for inhalation 
drug delivery and found better improvement over other modes of 
drug delivery. Huland et al. [25] administered interleukin-2 (IL-2) by 
inhalation with concomitant IFN-α administered to 15 patients with 
metastatic renal carcinoma and found improved response in lung 
compared with non-lung metastases propounding that inhalational 
IL-2 showed enhanced antitumor efficacy in pulmonary lesions. 
Nebulized IL-2 along with systemic IL-2 has also been assessed in 
renal cancer patients [26]. In recent studies, researchers have 
proved better treatment strategy by utilizing nanoparticles and 
nanocomposites via inhalation. Ching-Li Tseng et al. showed the 
effect of gelatin nanoparticles [7] and Insoo Kim et al. showed the 
effect of doxorubicin-loaded highly porous large PLGA 
microparticles against lung cancer via inhalation [27]. In addition, 
Samah Anabousi et al. showed the effect of transferrin-conjugated 
liposomes against Calu-3 cell line in vitro [28].  
Among diverse inhalation drug delivery systems biodegradable 
nanoparticles shows unique features (table 1) and potent 
advantages by means of protecting the active ingredient from 
degradation and releasing the drug in a controlled manner for 
prolonged periods of time. However, few efforts have been made to 
deliver anticancer agents using nanoparticles, liposomes, proteins, 
peptides and carbohydrates via an inhalation route, the prime 
limitations of these systems are instability during nebulization, drug 
leakage and associated drug adverse side effects [30]. With this 
background, this review will give an overview of the application of 
nanoparticles for pulmonary drug delivery via inhalation, anatomy and 
physiology of the lung and respiratory tract, deposition and biokinetics 
of inhaled nanoparticles, nanocarrier strategy for inhalation drug 
delivery, types of inhalers as well as inhalation studies on pulmonary 
carcinoma and its advantages. Recent results from invitro and invivo 
studies are included to underline the unique potential of inhalation drug 
delivery systems for the treatment of lung cancer. 
 
Table 1: Unique features of nanomaterials [29] 
 Size: 20–50 nm enters CNS<70 nm, able to  
escape defense system in vivo 
 High surface to mass ratio, strength,  
conductivity, solubility, durability and reactivity 
 Catalytic promotion of reactions 
 Ability to absorb and carry other compounds 
 Ability to cross cellular and sub-cellular membranes 
 Surface coating (e. g., lecithin, albumin) 
 Enhance uptake by Type I/II pneumocytes  
 Transcytosis across capillary 
 Charged particle (higher inhaled deposition) 
 
Lung and respiratory tract 
The predominant function of the lungs is to allow gaseous exchange 
between the blood and outside environment and to maintain pH 
equilibrium. A precise knowledge of lung physiology is an important 
prerequisite for the evolution of novel pulmonary delivery systems 
[12-14, 31]. The respiratory tract is bisected into two distinct tracts: 
the respiratory zone and the conducting airways. The conducting 
airways act as a gaseous transport system and include the 
mouth/nasal cavity, pharynx, larynx, trachea, bronchi and 
bronchioles. In the respiratory bronchioles and alveoli, the gaseous 
exchange takes place. The conducting airways display 16 
bifurcations followed by another 6 bifurcations of the respiratory 
bronchioles constitute the passage to the respiratory zone where the 
alveolar ducts along with alveolar sacs finally branch off. The 
thickness of cell layer of the air-blood barrier moderately subside 
from ≥10 μm in the tracheo -bronchial region to ≤0.3 –1 μm in the 
alveolar region (fig. 1). The barriers of the conducting airways are 
lined by an adhesive, viscoelastic mucus layer (5–55 μm thickness) 
produced by submucosal gland cells and goblet. The lumen of the 
bronchial airways is coated with a flimsy layer of serous fluid upon 
which floats a layer of mucus which helps to snare aerosolized 
particles. The dovetailed rhythmic beating of the cilia eternally 
moves this mucous layer toward the proximal airways where it is 
expectorated (mucociliary clearance). The major ingredients of 
respiratory mucus are water and glycoproteins [32-33]. Clearance of 
mucus from the lung is driven by the mobility of ciliated cells 
(broncho-tracheal escalator) which triggers a mucus flow rate of ~5 
mm/min. Hence, the respiratory mucus blanket is replaced every 
1/3 hrs in healthy subjects [33-34]. The physical, chemical 
properties (e. g. viscosity) and clearance of respiratory mucus 
usually vary in patients affected from respiratory diseases such as 
chronic obstructive pulmonary disease, cystic fibrosis and asthma 
[34]. There are about 300 million (approx) alveoli in the lungs with a 
combined facet area that is greater than 100m2 and with an alveolar 
epithelium as thin as 0.1 µm [14, 35]. This cosmic surface area, 
combined with a distinctly thin barrier between the capillaries and 
pulmonary lumen fabricates conditions that are well suited for 
effective mass transfer [35]. The alveolar space is lined by a complex 
surfactant lining that tapers surface tension to minimize the work of 
breathing and forbids collapse of the alveoli during expiration. The 
lung has a relative humidity of approximately 99.5%.  
 
 
Fig. 1: Schematic of the microstructure of the human 
respiratory tract–modified from [14] 
 
Drug particles are known to be hygroscopic and to grow or reduce in 
size under high humidity. The stretch in particle size above the 
initial size should affect the distribution of the aerosolized drug 
inside the lung [36-37]. Besides drug absorption could arise via the 
lymphatic pathway [38-39], the lung receives the complete cardiac 
output and represents the most perfect perfused organ in the body. 
However, only the alveolar portion is supplied by the pulmonary 
circulation. The endobronchial circulation is recirculated to the 
peripheral airways and lung parenchyma via the bronchial veins and 
right atrium. Bronchial blood flow is elevated in diseases such as 
bronchiectasis; from 1% to as much as 30% of cardiac output [18]. 
Conceptually, inhaled drugs that are assimilating into the circulation 
from the tracheobronchial regions can be recirculated downstream 
and peripherally into otherwise poorly accessible areas of the lung, 
which may aid in drug effectiveness [40]. However, the lung 
possesses clearance mechanisms and efficient barrier systems; 
much attention has been paid to this organ for gene and drug 
delivery applications. The broad alveolar surface area (~150 m2) is 
enfold by a capillary network less than 1 μm below the epithelial 
surface, from which diverse agents can be readily absorbed to the 
bloodstream [12, 31]. Moreover, aerosols are shown to possess 
effective treatment modalities for local respiratory diseases [12, 41]. 
However, conventional pulmonary dosage forms deficit controlled 
release properties. Thus, local and systemic inhalation therapies would 
benefit from pulmonary formulations which regulate release rates over 
extended periods of time [42, 43]. Among the diverse carriers mentioned 
for pulmonary applications, polymeric nanoparticles along with 
chemopreventive agents shows potential as controlled delivery devices 
due to sustained retention in the lung [44-49]. 
Deposition and biokinetics of inhaled nanoparticles 
Due to the effective clearance mechanisms of the lung, the possibility 
to control kinetics of the therapeutic compound remains an 
illustrious challenge. Particle deposition in the lungs arises by 
Gravitational sedimentation, Brownian diffusion and Inertial 
impaction as showed in table 2. 
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Table 2: Mechanism of aerosol deposition [12, 52] 
S. No. Mechanism Size (µm) Site 
1. Brownian Diffusion ≤0.5 Alveoli 
2. Impaction 5-9 (Slow Inhalation) 
3-6 (Fast Inhalation) 
Large Airways 
3. Gravitational Sedimentation 1-5 Smaller Airways 
4. Gravitational Sedimentation 1-3 Respiratory bronchioles 
 
Particles possess a mass median aerodynamic diameter (MMAD) 
more than 5 µm are predominantly exposure to inertial impaction 
happens during the passage through the pharyngeal region and 
large conducting airways. When the MMAD of particles ranging 
between 1 µm to 5 µm are allowed to sediment by gravitational 
force that appears in smaller airways and respiratory bronchioles, 
where delivered drug perchance anticipate having compact systemic 
therapeutic effect [35, 45, 53]. Sedimentation is governed by breath-
holding. Particles with a MMAD of lesser or equal to approximately 
0.5 µm, they are settled notably by diffusion and by means of 
Brownian motion. On the other side, particles with diameters 
markedly smaller than 1 µm are more credible to reach the alveolar 
region, but are not reliable to deposit and thus are exhaled. Particles 
with aerodynamic diameters (AD) between 1 µm and 5 µm are 
predict to detour deposition in the mouth and throat and deposit 
efficiently in the lung boundary [14, 45, 53-54]. Once deposited 
drugs confront a variety of biological and physicochemical barriers. 
These include macrophages in the alveolar region, catabolic 
enzymes and mucus barriers in the tracheo-bronchial region (fig. 2).  
 
 
Fig. 2: Various biological barriers to drug delivery via the lung-
modified from [50] 
 
Studies using plethysmography confirms that insertion of 5%-7% 
CO2 into the inhalation system exalt the depth of absorption and 
quantity of drug inhaled in each breath by lessening the respiratory 
rate and raising the tidal volume by 180%. The size, area and 
adequacy of particle deposition after inhalation is governed 
especially by three factors (physiology and aerosol properties) 
during breathing: (a) droplet/particle size (diameter), surface 
properties, density and shape [55]; (b) anatomy of the airways and 
the alveolar structure; and (c) parameters of ventilations with 
impact on the particle deposition are flow rates and tidal volume, 
breath pattern, determining the residence time and the airflow 
velocity in the respiratory tract [56-58]. Beside ventilation 
parameters and morphological characteristics, the particle size and 
geometry matters much [57]. The particle size is commonly referred 
to the AD, which is an irregular depending on the shape, density and 
size of the object. If aerosols contain disparate particles, the size 
distribution is generally characterized by MMAD, which is uniquely 
important to assume whether the particles will be efficiently 
deposited deep into alveolar region [13, 58]. A strong deposition 
into deep lung needs the particles is to be bitty enough to duck 
deposition by inertial impaction on upper airways and can move via 
the lower airways and be large enough to avoid exhalation [59-61]. 
The particle size for attaining delivery depth into alveolar region has 
been fixed to be an aerodynamic diameter between 1 µm and 3 µm 
[52]. In the lung, the deposition of particles however, is bi-model and 
ultrafine particles (<100 nm) appear to deposit effectively to the 
alveolar region (50%) as calculated from math-modeling of mono-
disperse particles after steady inhalation with a breath hold (fig. 3) 
[14, 51, 52].  
 
 
Fig. 3: Effect of particle size on the deposition of aerosol 
particles in the human respiratory tract following a slow 
inhalation and a 5 s breathe hold. Smaller particles deposit in 
the alveolar region whereas larger particles deposit in the 
airways or mouth and throat. Particles less than 1 µm can be 
exhaled, thereby bringing down deep lung deposition [51] 
 
Nanoparticle deposition in the lung and respiratory tract is 
determined by diffusional displacement as a result of thermal 
motion of air molecules combined with particles in the exhaled and 
inhaled air streams [62, 63]. Deposition occurs in all regions of the 
lung: the airways and the alveoli, usually depends on the particle 
size, shape and ventilation parameters. With truncate diameter in 
particle below 500 nm, the deposition augments in all regions of the 
lung due to the increasing diffusional mobility [61]. The deposition 
mechanism and uptake of nanoparticles in the lung along with 
different cell types were illustrated in fig. 4. Physical properties that 
show an outstanding role on the particle size of the inhaled 
suspension are osmolarity, pH, viscosity and ionic strength. If the 
values for osmolarity and pH are not in the normal range coughing, 
bronchoconstriction and irritation of the lung mucosa is induced 
[64, 65] and also it may leads to lung cancer incidence [66]. 
 
 
Fig. 4: The deposition mechanism and uptake of particles in the 
lungs along with different cell types [67] 
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Nano carriers and strategies in inhalation drug delivery 
In Inhalation drug delivery, nanoparticles have received hoisted 
debate due to their dominance in sustained drug release, targeted 
deposition, bioadhesion and reduced dosing frequency for enhanced 
comfort to the patient [68]. Some incentives for wield nanoparticles 
for the controlled delivery of drugs, genes, proteins, peptides, siRNA 
and also vaccines in the lung include having an imprecise size for 
circumventing alveolar macrophage clearance and assist 
transepithelial transport. Nanocarriers used for pulmonary 
applications also include solid lipid nanoparticles, liposomes and 
polymeric nanocarriers [69-71]. A diagrammatic representation of 
various approaches of nano based therapeutic system is showed in 
fig. 5. 
Solid lipid nanoparticles 
Solid lipid nanoparticles (SLN) are organic or synthetic lipid-based 
drug delivery system of size (50 to 1,000 nm) [72] and have globally 
been studied for a century for potential inhalation drug delivery. 
Some typical solid lipids which has been used to make SLNs include 
emulsifying wax, cholesterol, cholesterol butyrate, triglycerides 
(Dynasan 112), beeswax, carnauba wax and cetyl alcohol [73, 74]. 
SLNs are nanoscale aqueous suspensions obtained from primarily 
triglycerides, physiological lipids and phospholipids. Since, 
physiological components are widely used for the formulations of 
SLNs, they possess meagre toxicity and admissible for pulmonary 
drug delivery. Nassimi et al. [75, 76] revealed the benefits of 
triglyceride and phospholipid based SLN in the ratio of 70:30 for 
potential pulmonary applications. They also measured the cytokine 
activation measurements and toxicity profile of these SLN in invivo, 
exvivo and invitro models. They observed no activation of pro-
inflammatory cytokines (chemokine-KC and TNF-α) when the 
administration of SLNs in mice via nebulization [75, 76]. Paranjpe et 
al. demonstrated the toxicological effect of sildenafil-loaded SLN in 
exvivo and invitro models using heart and lung tissues obtained from 
murine models for the treatment of pulmonary arterial hypertension 
using pulmonary administration [77]. Due to the similar lipid matrix 
base utilized in the studies by Paranjpe and Nassimi, these SLN can 
be suitable for the pulmonary administration of API (active 
pharmaceutical ingredients) for the treatment of pulmonary 
diseases [76, 77]. In the studies performed recently, solid lipid 
microparticles loaded with quercetin (SLM) were shown to be 
possible treatment in asthma for the anti-inflammatory and 
antioxidant properties of the quercetin [78].  
 
Table 3: Different active pharmaceutical ingredient (API) molecules inculcated into various nanoparticle systems for pulmonary 
administration to treat lung cancer 
S. No. Drugs Nanoparticles References 
1. Silibinin SLN [111] 
2. Methotrexate Polymeric NP [112] 
3. Paclitaxel Polymeric NP [113–115] 
4. Cisplatin Dried NP [116, 117, 119] 
6. Doxorubicin Polymeric NP [27] 
7. Doxorubicin SLN [118] 
8. Idarubicin SLN [79] 
9. Ibuprofen SLN [120] 
10. Paclitaxel Liposome NP [88, 89] 
11. Endostatin Polymeric NP [94] 
12. Beclomethasone dipropionate Polymeric NP [90] 
13. pCMV-Luc gene Polymeric NP [98] 
14. Ibuprofen Dendrimer [102] 
 
 
Fig. 5: Diagrammatic representation of various approaches for cancer therapy and diagnosis-Modified from [139] 
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In the field of cancer biology, SLNs have been successfully designed 
as vehicle for delivery of various anticancer drugs such as paclitaxel, 
doxorubicin, camptothecin, idarubicin and etoposide due to its 
intrinsic ability to furnish enhanced bioavailability for water 
insoluble drugs [79]. The lung provides a high surface area by 
circumventing first-pass effects and also facilitates hasty drug 
absorption of aerosolized drugs as the walls of alveoli in the lung are 
especially thin [80, 81]. In studies done by Mussi et al. [82], 
doxorubicin loaded SLN was evaluated for anti-cancer potential and 
they come to the conclusion, that DOX-SLN possess cytotoxicity. In 
yet another study, apart from the delivery of anticancer drug by 
SLNs, they were used as a vehicle to deliver gene in invitro lung 
cancer cells (A549). In this work cationic SLN were loaded with anti-
microRNA for clampdown of microRNA-21 functions in lung cancer 
cells of human. Drugs that have been incorporated with the SLN for 
pulmonary administration to treat cancer are listed in table 3. 
Considering the potential benefit of SLN includes low toxicity and 
use of physiological phospholipid components, they still persist as 
an accepted drug delivery system even after more than couple of 
decades.  
Liposomes 
Liposomes are a captivating drug delivery system particularly for 
pulmonary applications, as it is obtained predominantly from 
phospholipids which are innate in lungs. Liposomes possess 
constant release properties which empowers the maximum drug 
effect over a prolonged period of time. The first liposomal product 
was introduced in 1990, which was called Alveofact® (purified 
bovine surfactant) for acute respiratory distress syndrome (ARDS) 
in infants via pulmonary instillation. Dry powder formulations of 
liposomes have been shown to be auspicious in the delivery of 
diverse pulmonary drugs and some of these drug formulations are in 
clinical trials. At present, two liposomal products are in the final 
stage of clinics, they are dry powder liposomes-Pulmaquin™ 
(ciprofloxacin, Aradigm Corp., Hayward, CA, USA) and Arikace® 
(amikacin, Insmed, Monmouth Junction, NJ, USA), for the treatment 
of lung infections [83-87]. In studies to fabricate liposome based 
drug delivery system for lung cancer therapy, Zhao L and his group 
in 2011 designed Tween-80/HSPC/cholesterol liposomes of 
diameter (501.60±15.43 nm) loaded with PTX [88-89]. In a study 
performed by Gjetting et al. in 2010 proved PEG-modified 
DOTAP/cholesterol liposome complex attained much better gene 
delivery system as compared to that of non-PEGylated counterpart 
[90]. 
Polymeric nanoparticles  
Polymeric nanoparticles dispense a typical platform for a perfect 
nanotheranostic drug delivery system. The adaptability in 
physiochemical alterations of polymer properties permits it to be 
adapting for drug encapsulation requirements. Aside from being 
biocompatible and biodegradable, these polymeric systems are 
competent of giving rise to sustained-encapsulated drug release 
profile. Moreover, these polymer systems have been designed to 
deliver proteins and nucleic acids to effectuate their therapeutic 
activity over target cancer cells. The most frequently used polymer 
systems for lung cancer therapeutics includes poly (lactide-co-
glycolide) (PLGA), Polylactic acid (PLA), Poly (ethyleneimine) (PEI), 
poly (ε-caprolactone) (PCL), chitosan, alginic acid and gelatin. 
  
Table 4: Polymer-based and metal nanoparticle based pulmonary therapeutic approaches to treat lung cancer 
S. No. Model system under study Therapeutic/Imaging agents Carrier molecule References 
1. Intravenous injection and aerosol inhalation 
in mice 
p53 Plasmid PEI [126-127] 
2. LLC bearing 
female C57BL/6 J mice 
pCMV β-gal PEGylated gelatin nanoparticle [128] 
3. Administered by parenteral routes or by oral, 
nasal, 
and pulmonary routes in rats 
Cyclosporine A, calcitonin, 
and somatostatin 
Solid lipid nanoparticles [129] 
4. Human bronchial cell line, Calu-3 cells T cell-specific surface 
antigen 
Glycerol and poloxamer-188 [130] 
5. Injected into C57BL/6 mice through 
intranasal route 
Firefly luciferase PEG-substituted PLL [131] 
6. A549 cell line Doxorubicin-HCl CNT-gold hybrid [132] 
7. A549 lung epithelial cancer cell line Doxorubicin-HCl DEX-MWCNTs [133] 
8. A549 and NCI-H460 cell lines Paclitaxel SWCNT-graphene oxide [134] 
9. A549 and HFL1 (human lung fibroblast) cell 
lines 
Magnetic dicalcium phosphate 
dihydrate 
Dicalcium phosphate dihydrate 
(DCPD) 
[135] 
10. H460 (human NSCLC cells) and female nude 
mice 




11. Human H460 lung cancer cells siRNA DOPA-coated calcium phosphate 
nanoparticle 
[137] 
12. Mice osteoblast and He99 lung cancer cell 
line 
Lac Z and enhanced green 
fluorescence 
protein gene (EGFG) 
Fe3O4 [138] 
 
The toxicity and biodegradability of carrier polymers are observed 
closely for pulmonary application, as remaining polymers can 
interact with the bio-surfactants occurs in the alveoli which can lead 
to a cascade of events eventually end up in critical breathing 
problems.  
Some of these polymer-based pulmonary therapeutic approaches 
have been enlisted in table 4.  
Poly (D, L-lactide-co-glycolide)  
PLGA is one of most successful Food and Drug Administration 
(FDA)-approved biodegradable polymers used for formulation of a 
nano-based drug delivery system. Aside from drugs, PLGA can be 
used for delivery of proteins and many biomolecules such as DNA, 
RNA, and peptides [91-93]. In specific to lung cancer, the polymer 
PLGA has proved to be a potential carrier molecule. In studies 
performed by Wu et al. [94], endostatin-loaded PLGA microspheres 
were designed by emulsification-evaporation technique and it could 
attain the required therapeutic effect at decreased concentration of 
drug thus circumventing predisposition of healthy cells to cytotoxic 
drugs. Sengupta et al. [95] designed bi-phospholipid-coated PLGA 
core nanoparticles wherein doxorubicin (doxo) is conjugated to 
PLGA while comberstatin is mixed with phospholipid and 
encapsulated in the outer lipid bilayer to effectively eliminate 
NSCLC. In another try by Nguyen et al. in 2008, H1299 luc cell lines 
were successfully transfected using tertiary-amine-modified PVA 
implant over PLGA as siRNA delivery construct. PLGA-PEG 
copolymeric nanoparticles were employed as a typical platform for 
Thiruvengadam et al. 
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coupling imaging agent super-paramagnetic iron oxide nanoparticle 
(SPION) and an anticancer drug molecule doxo hydrochloride as a 
potential theranostic strategy against lung cancer [84]. In yet 
another study recently performed by Rajan et al. in 2014, they 
showed the invitro anticancer effect of 2-isopropyl-5-methylphenol 
(IPMP) loaded PLGA based iron oxide nanoparticles (IMNPs) in liver 
cancer cell line [196].  
Poly (ethylene glycol)  
PEG is a biocompatible hydrophilic polymer which is infused in 
polymeric drug carriers to sustain their residence time in body to 
curtail their susceptibility to metabolic enzymes and decline their 
immunogenicity. In some cases, it has been used as such for delivery 
of therapeutic drugs to pulmonary cells because frequently it forms 
a component of copolymeric carrier molecules. In a study performed 
by Guthi et al. a multifunctional PEG-b-PDLLA (poly (D, L-lactide) 
micelle system inculcated with LCTP was loaded with SPIONs and 
doxo [96]. The formulation showed αvβ6-dependent cell targeting 
towards H2009 lung cancer cells with competent specificity. 
PEGylated phospholipid-polyaminoacid conjugate copolymer has 
also been used for effective delivery of Beclomethasone 
dipropionate (BDP) to lung carcinoma cells. In another study, cross 
linked PEG thiol with 1, 6-hexane-bis-vinylsulfone (HBVS) was 
proved as a stable nanogel for pulmonary therapy. The construct 
was verified with a fluorescent dye HiLyte Fluor 750 (AnaSpec Inc., 
USA) and was finalized by applicable imaging system [90]. In recent 
study performed Rajan et al. in 2015, they evaluated the toxicity 
profile of polyethylene glycol-8000 coated ultra-small 
superparamagnetic Iron oxide nanoparticle (PUSPIOs) which is 
intravenously administered on wistar rats and they found PUSPIOs 
posses excellent biocompatibility and wistar rats showed much 
better drug tolerance to the dose of 10 mg/kg. b. w per week than 
the dose of 10 mg/kg. b. w twice a week for the period of 30days 
[197].  
Chitosan  
Chitosan possesses numerous ionisable amino groups which could 
be scaled simply to provide the need for the delivery of the 
therapeutic agent. Due to its non-toxic, bio-adhesive and 
biodegradable properties, it has led to its global application in drug 
delivery. It is usually employed for the delivery of nucleic acids to 
lung cancer cells due to its cationic nature. Dried as powdered 
chitosan was assessed as a bearer for intratracheal delivery of 
pCMV-Muβ-encoding murine interferon-β in mice pre-inculcated 
with significant doses of CT26 cells [97]. Okamoto et al. used low 
molecular weight chitosan as a vector for delivering pCMV-Luc gene 
into the lung cancer cells via nasal route into the mice model [98]. 
The predominantly administered anticancer drug for NSCLC is 
paclitaxel (PTX). A chitosan derivative, [N-((2-hydroxy-3-
trimethylammonium) propyl) chitosan chloride (HTCC)] was 
scrutinized as a carrier for PTX [99]. These PTX-loaded HTCC 
nanoparticles (HTCC-NP: PTX) were evaluated for invitro cell 
viability and they posses better accumulation in subcutaneous 
tumor tissues as a consequence of hoisted permeability and 
retention (EPR) effect. In a study demonstrated by Ventura et al. 
chitosan-dextran-based delivery system was used to deliver 
gemcitabine and they showed the efficacy of gemcitabine against 
NSCLS cells [100].  
Dendrimers  
Dendrimers carries its own importance in the field of cancer 
diagnosis and therapeutics [101]. The utility of wide range of surface 
functionalization of dendrimers with therapeutic, targeting and 
diagnostic molecules dispense the scope for effective therapy and 
diagnosis of lung cancer. The ibuprofen delivery by poly 
(amidoamine) (PAMAM) dendrimers and hyper branched polyol 
polymers has been studied in A549 human lung epithelial carcinoma 
cells. In recent past, Starpharma Holdings Ltd (pharmacy company) 
has came up with dendrimer-doxorubicin formulation which on 
intratracheal administration to rats shown to yield significantly 
augmented efficacy in preventing lung metastases as compared to 
that of the drug alone [102]. A new insight to deliver nucleic acids by 
dendrimers came into existing when a research group reported 
increased penetration efficiency and improved stability of small 
interfering RNA (siRNA) by using surface-engineered poly 
(propyleneimine) (PPI) dendrimers. The specificity and efficacy of 
these nanoparticles were then strengthened by invivo experiments 
[103]. In a studies investigated by Rahbek, successfully transfected 
H199 human lung cancer cell line with pre-miRNA EGFP by a similar 
rHB-based formulation [104]. Liu et al. have successfully conjugated 
fluorescent-labeled molecule (FITC) and lung cancer-targeting 
peptide (LCTP) on the surface of acetylated derivative of PAMAM 
(4G) dendrimer [105]. This system showed concentration and time 
dependent cellular uptake under invitro conditions and in athymic 
mice, it was hence established as a potential drug carrier for 
targeted cancer nanotheranostic.  
Poly (ethyleneimine)  
With regard to gene therapy for cancer cells, the polymer which is 
used frequently for this purpose is PEI due its capacity to form 
highly stable polyplexes with nucleic acids. For the purpose to hoist 
the hydrophobicity of PEI-based delivery system and thereby 
permits its facile transit across the membrane, cholesterol molecule 
has been conjugated to PEI. Due to mucoadhesive nature, a team of 
research group scrutinized PEI-derived aerosol system for topical 
gene delivery (p53) to the lungs of B16-F10 murine melanoma mice 
model [106]. Zhou et al. demonstrated PEI-based carrier for delivery 
of therapeutic gene which destruct the expression of metastatic 
signals by lung cancer cells [108]. In another studies performed by 
Hong et al. they developed glycerol triacrylate-spermine (GT-SPE), a 
polyspermine as a gene carrier for transfection of lung cancer cells 
with small hairpin Akt1 (shAkt1) RNA. The delivery of shAkt1 in a K-
ras (LA1) lung cancer mice model was shown to procure apoptosis 
in target lung cancer cells [107]. 
PEG-based copolymeric systems 
Among few PEG-based combinational polymeric drug delivery 
systems, the most predominant one were PEG-PCL and PEGPEI. A 
notable development in the transfection efficiency of PEI-based gene 
delivery polymers against the lung tumor cells was obtained by 
Kleemann et al. when they conjugated protein transduction domain 
[HaIV-1 TAT] over PEI by means of hetero bi-functional PEG spacer 
molecules [109]. The efficacy of TAT-PEG-PEI composite was trailed 
by the level of expression of luciferase in A549 cells and in mice after 
intratracheal instillation. In another studies performed by 
Dhananjay et al. they showed Akt1 shRNA delivery in lung cancer 
cells using a novel biodegradable polymeric carrier molecule 
consisting of PEI-PEG copolymer. The Akt1 shRNA-mediated 
silencing of oncoprotein Akt1 induced specific apoptosis in lung 
cancer cells [110].  
Metal-based nanoparticles for inhalation drug delivery 
Every day, we regularly get in touch with metal nanoparticles 
(MNPs) through various means such as food, medicine, water and 
cosmetics, as they are globally used in a variety of daily things. Some 
of these MNPs have attained cytotoxic effects on lung cells. Some of 
the MNPs which are used in lung cancer therapy and diagnosis are 
showed in table 4. Among various nanoparticles, gold nanoparticles 
(AuNPs) have been effectively studied for lung cancer therapy and 
diagnosis. In a studies performed by Hu et al. a photothermal 
therapeutic agent has been developed by hollow Au/Ag 
nanostructures along with a dendritic morphology for the 
eradication of A549 lung cancer cells [121]. Additionally, AuNPs 
cross linked with methotrexate, an analog of folic acid, also 
developed a cytotoxic effect in LL2 (Lewis lung carcinoma) [87]. In 
2012, Barash et al. proposed a nanodevice based on AuNPs sensors 
that categorize the lung cancer histology by recognizing the lung 
cancer-specific patterns of volatile organic compound profiles. Silica 
nanoparticles are globally used in diverse biomedical applications 
such as biomarkers for tumor identification, biosensors for bio-
molecular assay and drug delivery agents in cancer therapy due to 
its biocompatibility and swift renal clearance. In a studies performed 
by Yoon et al. they reported that the A549 lung cancer cells taken up 
the multifunctional magnetic nanoparticles such as cobalt ferrite 
with high specificity, encapsulated inside silica shell along with 
imaging agent (FITC–organic dye) and a tumor-targeting antibody 
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(Ab CD-10) [122]. The cytotoxicity of silver nanoparticles (Ag NPs) 
to various cell lines is evaluated by necrosis and apoptosis 
mechanisms, which are in turn facilitated by altering up-regulating 
apoptotic signaling molecules and membrane structure [123-125]. 
Supermagnetic iron oxide is extensively used as a MRI imaging 
agent, which if combined with a suitable carrier molecules and 
targeting agents, can be used for cancer therapeutic applications 
[196]. In an investigation to develop such a theranostic system for 
pulmonary carcinoma, these NPs along with the anticancer drug 
doxo, were inculcated within MFM system [96]. 
Inhalation drug delivery devices 
The formulations for inhalation drug should comprise a precise 
particle size, in the range of 1–3 µm to acquire substantial alveolar 
deposition. Inhaled molecules with this size becomes captured in the 
alveoli and taken up in vesicles by alveolar epithelial cells, so that 
they can be fetched across and released on the other side in the 
narrow interstitial fluid partition between the epithelial cells. 
Molecules are then taken up inside the vesicles by the endothelial 
cells transported across the girth of these cells and delivered into 
the alveolar capillary bloodstream. Aerosols are an effectual method 
to release therapeutic agents to the lungs.  
Nebulizers, Metered dose inhalers (MDIs) and Dry powder 
inhalers (DPIs) are commonly used to generate aerosols [140, 
141]. All three types of devices use diverse mechanisms for 
delivery of drugs and hence require various types of drug 
formulations. Images of some of the available and approved 
inhaler devices are shown in fig. 6. 
 
 
Fig. 6: Images of some currently available inhaler devices: Dry Powder Inhalers-(A) Aerolizer®(B) Easyhaler®, (C) Turbohaler®, (D) 
Diskhaler®, (E) Novolizer®, (F) Clickhaler®, (G) MAGhaler®, (H) Spinhaler® and (I) Handihaler®, Nebulizers–(J) Pari Trek S® Portable 
Nebulized (K) Mechanism of Nebulizer (L) Nebulizers designed for Mice and Rat, Meter Dose Inhalers–(M) Image and Mechanism 
 
Nebulizers 
Nebulizers represent a remarkable technology for drug delivery to 
the lungs. Nebulizers have been used for decades to medicate 
different respiratory diseases. They usually work by inhalation 
through a face mask and can be used in respiratory problems. 
Moreover, they can deliver substantial quantities of suspensions and 
solutions as small droplets which require remarkably compact 
patient coordination. At present, there were two basic types of 
nebulizers, i.e., ultrasonic nebulizers and jet nebulizers. Jet 
nebulizers take benefits of the energy provided by flowing of 
compressed gas and distribute the liquid substance in the reservoir 
cup into a fine mist. Jet nebulizers are extensively used but are 
rather scarce (50% loss when continuously operated and only 10% 
deposited to the lungs) in comparison with the novel devices 
described below [142]. Their performance is mainly dependent on 
the compressor used [143-144]. The ultrasonic nebulizers utilize a 
piezoelectric crystal that vibrates at a high frequency (1–3 MHz) to 
fabricate a mist of liquid in the nebulizer. Ultrasonic nebulizer 
solutions are faster than jet nebulizers but are not suit for 
suspensions. Besides, the piezoelectric crystal can heat and 
inactivate protein-based drugs [145]. Kleinstreuer et al. have 
showed data concerning the optimal conjugation of particle size, 
inhalation waveform and particle release position that may release 
inhaled drug aerosols effectively to the respective areas [146-147]. 
Nebulizers produce ultra fine droplets (1 mm) with a maximum 
degree of polydispersity and particles outsize than the droplet size 
have been reported not to be aerosolized [148]. Due to this 
rationale, nebulizers may not be suitable for delivering huge 
particles to the lungs. 
Metered dose inhalers (MDIs) 
Metered dose inhalers (MDIs) are pressurized repository that 
contain drug that is either suspended or dissolved in a liquid 
propellant (usually hydrofluoroalkanes-HFA) [149]. The aerosol is 
discharge through a nozzle at a high velocity of>30 msec). When 
operated, the device discharge a metered volume of propellant and 
drug through a valve system [150]. However dosing with MDIs is 
usually more reproducible than DPIs, MDIs are mostly more tedious 
to use because they need coordination between activation and 
inhalation to secure optimal deposition of drug in the lungs [149, 
151]. Another drawback of MDIs is their use of HFA propellants, 
which have been associated with global warming [149]. In addition, 
MMDIs also contain surface active agents like surfactants which may 
influence lung performance [149]. 
Dry powder inhalers (DPIs) 
DPIs are breath-actuated devices that administer a dry powder drug 
via shear-induced aerosolization [150]. Due to this, the actual dose 
delivered from a DPI is mainly dependent on the flow rate of 
inspiration and can sometimes be tough to replicate [149-152]. Dry 
powder inhalers were fabricated to vanquish poor actuation-
inhalation coordination. Factors affecting disaggregation are hoisted 
humidity, slow inhalation flow rate, quick and large variance in 
temperature. Failure to use the device properly is a usual error and 
therefore a dose is not released directly [153]. Dry powder inhalers 
that are at present in the market are breath-actuated and still rely 
on the flow rate of inhalation of the patient to attain utmost drug 
dose inhalation [154-155]. In addition, inhalers that utilize electro 
hydrodynamic spray or electrospray are also being explored. In this 
mechanism, nebulization of the liquid droplets depends solely on 
dispersion and electric charging occurs due to the Coulombic forces 
between droplets. This technique has been shown to keep the 
structure of proteins and has been referred as a method to release 
insulin to the lungs for the treatment of diabetes [156]. Moreover, 
electrospray offers superior control over droplet size dispensation 
being able to reach monodispersity [157-158]. One disadvantage of 
electrospray is that highly conductive solutions such as salt 
solutions may be extremely conductive (and thus will not hold a 
charge) to reach the target droplet size [157]. 
Soft mist inhalers 
At present, there is only one drug system of this particular type is 
available, which is a mechanical achievement of exceptional value. It 
relies on the energy of a spring to force the solution through an 
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immensely fine nozzle system [159-160]. It fabricates a fine aerosol 
with reasonably elevated lung deposition [161-163]. 
Inhalation studies on pulmonary carcinoma 
With regard to pulmonary carcinoma, there is enough published 
data regarding aerosol delivery of chemotherapy in animal models, 
cancer cell cultures and in phase I/II human studies (table 5). For 
the first time, Tatsamura et al. in 1993 published the reports of 
aerosolized chemotherapy in lung cancer [24]. In this preliminary 
study, 5-fluorouracil (5-FU) (250 mg in 5 mL) was delivered via 
inhalation using a nebulizer in patients with NSCLC. Six clinical 
responses were observed including four imperfect responses and 
two complete responses without any other significant pulmonary or 
systemic side effects. Later, many research group have been 
investigated various respiratory diseases via inhalation drug 
delivery system. 
  
Table 5: Published studies using inhalation chemotherapy for Lung cancer 
S. No. Authors Drugs  Subjects Inhalation device Reference 
1. Zarogoulidis et al. CARBO Human Nebulizer 180 
2. Tatsumura et al. 5-FU Human Supersonic Nebulizer 181 
3. Tatsumura et al. 5-FU Human Nebulizer 24 
4. Wattenberg et al. 5-FU Animal Nebulizer 182 
5. Hitzman et al. 5-FU In vitro, Animal Nebulizer 183 
6. Hershey et al. PTX DOX Animal Nebulizer 178 
7. Koshkina et al. 9-NX PTX Animal Nebulizer 184 
8. Knight et al. PTX CYS A Animal Nebulizer 185 
9. Wittgen et al. CIS Human Nebulizer 186 
10. Wittgen et al. CIS Human Jet Nebulizer 187-188 
11. Selting et al. CIS Animal Nebulizer 20 
12. Tseng et al. CIS In vitro, Animal Nebulizer 7 
13. Gagnadoux et al. GEM Animal Micro sprayer 189 
14. Koshkina et al. GEM In vitro, Animal Jet nebulizer 184 
15. Gagnadoux et al. GEM In vitro, Animal Nebulizer 190 
16. Min et al. GEM Animal Nebulizer 191 
17. Lemarie et al. GEM Human Nebulizer 173 
18. Azarmi et al. DOX In vitro Spray freeze-drying 192-193 
19. Otterson et al. DOX Human Nebulizer 194 
20. Roa et al. DOX Animal DP-4M insufflator 117 
21. Knight et al. 9NC Animal Nebulizer 175 
22. Lawson et al. 9NC Animal Nebulizer 195 
Abbreviations: DOX, doxorubicin; CIS, cisplatin; PTX, paclitaxel; 9NC, 9-nitro-camptothecin; CARBO, carboplatin; GEM, gemcitabine; 5-FU, 5-
fluorouracil and CYS A, cyclosporine 
 
In the studies performed by Ying yang et al. and his group, they 
showed the chemopreventive efficacy of Polyphenon E on lung 
tumor induced invivo model [21]. Polyphenon E (Poly E) was 
administered by aerosol delivery to A/J mice beginning 2 weeks 
after carcinogen treatment and continuing daily by inhalation 
throughout the remainder of the study (20 weeks). Poly E decreased 
tumor load by 59%. These results indicate that aerosol delivery of 
Poly E may be a useful chemopreventive protocol in subjects at high 
risk for lung cancer (fig 7.3). In addition, the chemopreventive 
efficacies of many compounds were investigated by means of 
inhalation drug delivery system. Budesonide [164], Isotretinoin 
[165], Transferrin-conjugated liposomes [28], Celecoxib [166, 167], 
Urocanic acid [168], Diindolylmethane derivative [169], 
Cyclosporine [22] and many such compounds were well studied 
using inhalation drug delivery for the treatment of lung cancer.  
In the studies revealed by Ching-Li Tseng et al. and his group, they 
came out with simple aerosol delivery for the treatment of lung 
cancer by administering biotinylated-EGF-conjugated gelatin 
nanoparticles targets to the EGFR-overexpression cancer cells invivo 
(fig 7.2) [11]. In another study, a tumor targeted mesoporous silica 
nanoparticles (MSN)-based drug delivery system (DDS) was 
developed for inhalation treatment of lung cancer [170]. The system 
was able to effectively deliver the anticancer drugs (doxorubicin and 
cisplatin) combined with two types of siRNA targeted to MRP1 and 
BCL2 mRNA inside the cancer cells in non-small cell lung carcinoma. 
Wang et al. [171] investigated the cytotoxic properties of farnesol 
nebulized by two different nebulizers Proneb Ultra compressor 
(Pari, Sternberg, Germany)] driven by a [Pari LC Star and LC Plus 
(vented, valved jet nebulizers) in two NSCLC cell lines (NCIH460 ET 
A549). This study showed the cytotoxic properties invitro of farnesol 
are not altered by nebulization. Gemcitabine (GCB) is a 
chemotherapeutic agent, has been shown to be effective in the 
treatment of NSCLC [172], both as monotherapy and in combination 
with other drugs The GCB formulation does not possess any 
chemical compound incompatible with aerosol delivery. These 
benefits, combined with solubility in saline and the dearth of irritant 
effects make GCB an attractive candidate for local administration. 
Likewise, cytotoxic properties have been observed with nebulized 
GCB against NCI-H460 and A549 NSCLC cells [173]. It caused 50% 
growth inhibition similar to that previously observed with non-
nebulized GCB. Diverse proof concept studies of aerosolized 
chemotherapy have been demonstrated in invivo models of 
metastatic lung cancer [174-176].  
In these studies, animals were exposed to the aerosol generated by a 
jet nebulizer in a sealed plastic box (fig. 6. L). Amount of drug settled 
in the lungs was estimated by taking into consideration that the 
concentration of drug in aerosol volume, the volume of air inspired 
by the animal/min, the estimated deposition index and the period of 
treatment (30 to 120 min). Using this strategy, the efficacy of 
aerosolized chemotherapy with liposome-encapsulated 9-
nitrocamptothecin (L-9NC) was investigated in two different 
experimental lung metastasis models [175]. A curative effect of 
aerosolized L-9NC was observed with fewer lung metastases in treated 
mice. In another study, the antitumor potential of a liposomal 
formulation of paclitaxel delivered to the lungs by aerosol was studied in 
the RENCA (Murine Renal Cell Carcinoma) model [174].  
Aerosols were initiated the day after renal carcinoma cell 
inoculation and were delivered for 2 weeks of time. A control group 
of mice received aerosols of blank liposomes. The study showed a 
preventive effect of liposomal paclitaxel aerosols delivered 3 days 
per week with a lessen number of visible lung metastases and 
prolonged survival compared to control groups. In the studies 
performed by Ho-Young Lee et al. showed the inhibition of 
oncogenic K-ras signaling by aerosolized gene delivery in a mice 
model of human lung cancer [177].  
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Fig. 7.1: An illustrated cartoon for the understanding of anti-




Fig. 7.2: The invivo fluorescence images of tumor-induced mice 
following aerosol delivery 24 h later by treatment with different 
nanoparticles solution: PBS-treated group (a), GP-Av-treated group 
(b), and GP-Av-bEGF conjugate-treated group (c). FITC green 
fluorescence spectra were obtained from live mice xenografted 
with the human lung adenocarcinoma cells (A549) [11] 
 
 
Fig. 7.3: Efficacy of aerosolized Poly E against B(a)P-induced mouse 
lung tumorigenesis. Light photomicrographs of representative 
adenomas from the control group (a & c) and the Poly E group (b & 
d) at 100x and 400x magnifications, respectively [21] 
 
Fig. 7.4: Histology of lung tissues in the four study groups at 4 
weeks after B16F10 cell implantation (5 X105 ea, 0 day) and/or 
pulmonary administration of Dox PLGA MPs (5, 14 day). (a) age-
matched treatment naive control mouse; (b) Dox PLGA MP 
administered mouse; (c) B16F10-implanted mouse; and (d) 
B16F10-implanted and Dox PLGA MPs administered mouse [27] 
 
In a study performed by Hershey et al. treated 24 anesthetized dogs 
with developed stages of spontaneous primary lung cancer or 
metastases with doxorubicin or paclitaxel aerosols administered 
twice weekly [178]. Tumor suppression was achieved in 25% of 
dogs with significant tumors without any systemic side effects 
usually associated with i.v. administration of these drugs and 
without pulmonary toxicity in the dogs treated with paclitaxel. In a 
studies demonstrated by Ajay Gautham et al. clearly explained the 
aerosol delivery of PEI–p53 complexes which inhibits B16-F10 lung 
metastases through regulation of angiogenesis [179]. Insoo Kim et 
al. in 2012 and his group fabricated doxorubicin-loaded highly 
porous large PLGA microparticles for the treatment of metastatic 
lung cancer via inhalation and they found Dox PLGA MPs have great 
potential as a long-term inhalation agent for the treatment of lung 
cancer (fig 7.1 & 7.4) [27]. At present, the study of inhaled 
doxorubicin combined with platinum-based therapy by Gregory et 
al. is in the phase I/II clinical trial for advanced NSCLC [180].  
CONCLUSION 
While nanomaterials renders significant assurance in medicine and 
healthcare, the potential risk enforced by natural and engineered 
nanomaterials has also been of concern. This is due to their 
enhanced activity at the nano-level. The unity of nanotechnology and 
pulmonary delivery of drug aerosols develops a new and 
intoxicating boundary for pharmaceutical dosage and design to 
elevate bioavailability and patient compliance, as assisted by the 
results of studies using nanoparticles as either therapeutic or 
diagnostic agents for lung and systemic diseases. Inhaled 
chemotherapy dispenses feasible treatment modality and offers 
many advantages. The reduction in particle size leads to an elevation 
in surface area leading to enhanced dissolution rate and also 
relatively equal distribution of drug dose among the alveoli. In 
addition, by inculcating the drugs in nanoparticles, one can attain a 
dose that is higher than that offered by a pure aqueous solution, 
which is thermodynamically restricted by the aqueous solubility of 
the drug. Nanocarrier systems can spare the benefits of sustained-
release in the lung tissue leading to reduced dosing frequency and 
improved patient compliance. Local delivery of inhalable 
nanocarriers may be an optimistic alternative to oral or intravenous 
administration, thus minimizing the incidence of side effects 
associated with a high drug serum concentration. 
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